PMID- 15147144
OWN - NLM
STAT- MEDLINE
DCOM- 20041116
LR  - 20161018
IS  - 1434-6621 (Print)
IS  - 1434-6621 (Linking)
VI  - 42
IP  - 4
DP  - 2004 Apr
TI  - Intravenous immunoglobulin (IVIG): modes of action in the clinical management of 
      recurrent pregnancy loss (RPL) and selected autoimmune disorders.
PG  - 359-70
AB  - Recurrent pregnancy loss has been associated with autoimmune responses to 
      membrane phospholipids and alloimmune reactions against paternally derived 
      molecules on the trophoblast. The problem is psychologically and economically 
      stressful as it undermines the capacity of some couples to reproduce and 
      participate effectively in the day-to-day economic activities. This article 
      reviews the adoption of intravenous immunoglobulin as a form of therapy for the 
      clinical management of recurrent pregnancy loss and of selected autoimmune 
      disorders. Side effects, contraindications and safety of use are discussed.
FAU - Omwandho, Charles O A
AU  - Omwandho CO
AD  - Department of Biochemistry, University of Nairobi, Nairobi, Kenya.
FAU - Gruessner, Susanne E M
AU  - Gruessner SE
FAU - Roberts, Timothy K
AU  - Roberts TK
FAU - Tinneberg, Hans Rudolf
AU  - Tinneberg HR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Abortion, Habitual/immunology/*therapy
MH  - Autoimmune Diseases/immunology/*therapy
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - *Immunotherapy
MH  - Pregnancy
MH  - Pregnancy Complications/immunology/therapy
RF  - 100
EDAT- 2004/05/19 05:00
MHDA- 2004/11/17 09:00
CRDT- 2004/05/19 05:00
PHST- 2004/05/19 05:00 [pubmed]
PHST- 2004/11/17 09:00 [medline]
PHST- 2004/05/19 05:00 [entrez]
AID - 10.1515/CCLM.2004.065 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2004 Apr;42(4):359-70. doi: 10.1515/CCLM.2004.065.